NASDAQ:GILD
69.04
0.39
(0.57%)
Gilead Sciences is an American biopharmaceutical company that discovers, develops and commercializes drugs.
More at Wikipedia
Analysis and Opinions about GILD-Q
Signal
Opinion
Expert
Chart
WEAK BUY
WEAK BUY
January 18, 2021
It is a healthcare name recently valued by investors. She likes to see a more visible pipeline in companies she buys. But this is a reasonable investment in this space.
Show full opinionHide full opinion
It is a healthcare name recently valued by investors. She likes to see a more visible pipeline in companies she buys. But this is a reasonable investment in this space.
BUY
BUY
December 7, 2020
They had good news about new drugs recently, but the stock still sold off. That's a sell signal.
Show full opinionHide full opinionThey had good news about new drugs recently, but the stock still sold off. That's a sell signal.
SELL STRENGTH
SELL STRENGTH
November 13, 2020
It's bottoming because of interest rates. Sell it at $65. You can also swap this for Bristol-Myers.
It's bottoming because of interest rates. Sell it at $65. You can also swap this for Bristol-Myers.
WATCH
WATCH
October 30, 2020
Likes the story. It has been frustrating since they like the story but the stock price has not reflected this. He thinks it is still undervalued. The core HIV franchise is stable and growing which gives good stability.
Show full opinionHide full opinionLikes the story. It has been frustrating since they like the story but the stock price has not reflected this. He thinks it is still undervalued. The core HIV franchise is stable and growing which gives good stability.
TOP PICK
TOP PICK
October 27, 2020
Stockchase Research Editor: Michael O'Reilly As the first developer of COVID-19 treatment with its remdesivir (approved by the FDA). The product will be sold under the name of Veklury for patients that need hospitalization. This follows recent new treatments, one for breast cancer and another for HIV. Although the drugs are expensive, they have been proven to be effective in their treatment. We would buy this with a stop-loss at $50. Yield 4.53% (Analysts’ price target is $78.65)
Show full opinionHide full opinionStockchase Research Editor: Michael O'Reilly As the first developer of COVID-19 treatment with its remdesivir (approved by the FDA). The product will be sold under the name of Veklury for patients that need hospitalization. This follows recent new treatments, one for breast cancer and another for HIV. Although the drugs are expensive, they have been proven to be effective in their treatment. We would buy this with a stop-loss at $50. Yield 4.53% (Analysts’ price target is $78.65)
DON'T BUY
DON'T BUY
October 23, 2020
It has had a spotty history. It gained wide acknowledgement from their Hep C drug. The stock traded at an expanded multiple. The difficulty was that it was a solution and not a treatment, which means there is a terminal value. This is great for society but not for a business. They made acquisitions in the oncology department which hasn't done much since. It is an iteration for the company and not an embedded value.
Show full opinionHide full opinionIt has had a spotty history. It gained wide acknowledgement from their Hep C drug. The stock traded at an expanded multiple. The difficulty was that it was a solution and not a treatment, which means there is a terminal value. This is great for society but not for a business. They made acquisitions in the oncology department which hasn't done much since. It is an iteration for the company and not an embedded value.
DON'T BUY
DON'T BUY
October 20, 2020
Very disappointing. They had their hepatitis C franchise that generated high cash flow, but they poorly invested this cash. They also lead in They have remdesivir, the first Covid treatment. So, he held onto Gilead over the summer, but remdesivir didn't turn out to be the big cure. Their M&A hasn't been productive, either. They recently made a very pricey acquisition which diversifies their business, but the price they paid was too highl they really need to execute. It's a value trap. He sold his shares six weeks ago.
Show full opinionHide full opinionVery disappointing. They had their hepatitis C franchise that generated high cash flow, but they poorly invested this cash. They also lead in They have remdesivir, the first Covid treatment. So, he held onto Gilead over the summer, but remdesivir didn't turn out to be the big cure. Their M&A hasn't been productive, either. They recently made a very pricey acquisition which diversifies their business, but the price they paid was too highl they really need to execute. It's a value trap. He sold his shares six weeks ago.
HOLD
HOLD
October 9, 2020
A big healthcare company. It has recently had a tough go, but they are still positive on it. Their HIV franchise continues to expand. The new management team has a good growth strategy that he views positively. Their oncology acquisitions were good moves. The assets were not cheap so execution needs to come through.
Show full opinionHide full opinionA big healthcare company. It has recently had a tough go, but they are still positive on it. Their HIV franchise continues to expand. The new management team has a good growth strategy that he views positively. Their oncology acquisitions were good moves. The assets were not cheap so execution needs to come through.
TOP PICK
TOP PICK
May 11, 2020
In the race to find a treatment, Gilead currently leads with its remdesivir. It's the name on every investor's lips and trading screens. Tests so far indicate that remdesivir shortens the recovery time of some Covid-19 patients, specifically those who take remdesivir recover after 11 days, which is four days faster than those who did not take it. Last week, the American FDA allowed doctors to use this drug on an emergency basis on patients hospitalized with Covid-19.
However, the FDA has not formally approved remdesivir, because it requires more testing. Currently, there are several ongoing clinical trials to test whether the drug can stop Covid-19 from replicating. In other words, remdesivir helps some patients heal faster, but isn't the magic bullet, at least not yet. In this horse race, Gilead is out front, but will it cross the finish line faster.
Gilead pays a 3.4% based on a payout ratio of 65.9%, and trades at a PE just under 20x, with a forward PE of 13x.
Show full opinionHide full opinionIn the race to find a treatment, Gilead currently leads with its remdesivir. It's the name on every investor's lips and trading screens. Tests so far indicate that remdesivir shortens the recovery time of some Covid-19 patients, specifically those who take remdesivir recover after 11 days, which is four days faster than those who did not take it. Last week, the American FDA allowed doctors to use this drug on an emergency basis on patients hospitalized with Covid-19.
However, the FDA has not formally approved remdesivir, because it requires more testing. Currently, there are several ongoing clinical trials to test whether the drug can stop Covid-19 from replicating. In other words, remdesivir helps some patients heal faster, but isn't the magic bullet, at least not yet. In this horse race, Gilead is out front, but will it cross the finish line faster.
Gilead pays a 3.4% based on a payout ratio of 65.9%, and trades at a PE just under 20x, with a forward PE of 13x.
COMMENT
COMMENT
March 20, 2020
US Healthcare? Healthcare generally under-preforms in election years. A safer pick would be GILD, for their COVID-19 research and HIV drugs.
Show full opinionHide full opinionUS Healthcare? Healthcare generally under-preforms in election years. A safer pick would be GILD, for their COVID-19 research and HIV drugs.
COMMENT
COMMENT
March 20, 2020
US Healthcare? Healthcare generally under-preforms in election years. A safer pick would be GILD, for their COVID-19 research and HIV drugs.
Show full opinionHide full opinionUS Healthcare? Healthcare generally under-preforms in election years. A safer pick would be GILD, for their COVID-19 research and HIV drugs.
TOP PICK
TOP PICK
March 11, 2020
He likes the yield. He believes they are making some headway on a CVT-19 drug on trial in China. They are also doing more M&A to bring innovation into their pipeline. They are working on liver disease drugs and HIV drugs. They have a clean balance sheet as well. Yield 3.68% (Analysts’ price target is $75.22)
He likes the yield. He believes they are making some headway on a CVT-19 drug on trial in China. They are also doing more M&A to bring innovation into their pipeline. They are working on liver disease drugs and HIV drugs. They have a clean balance sheet as well. Yield 3.68% (Analysts’ price target is $75.22)
DON'T BUY
DON'T BUY
February 25, 2020
It's a little speculative, because they could invent the coronavirus vaccine. In the past they found the hepatitis C cure. Gilead did very well until a few years ago. Now, their earnings and stock are half of their historic peak.
Show full opinionHide full opinionIt's a little speculative, because they could invent the coronavirus vaccine. In the past they found the hepatitis C cure. Gilead did very well until a few years ago. Now, their earnings and stock are half of their historic peak.
DON'T BUY
DON'T BUY
January 30, 2020
It is less of a diversified company than big pharma. He is not big on investment in this sector. It is a tough place to be. It would be better at a lower price.
Show full opinionHide full opinionIt is less of a diversified company than big pharma. He is not big on investment in this sector. It is a tough place to be. It would be better at a lower price.
DON'T BUY
DON'T BUY
January 17, 2020
Very disappointing. The update from the new CEO wasn't particularly exciting. Their HIV prep drugs is doing well. However with the Hepatitis C drug coming off patent, they have lost revenues. Deep value but they need to execute. They like the high yield with great premiums on the options. He would rather own another diversified biotech or a basket.
Show full opinionHide full opinionVery disappointing. The update from the new CEO wasn't particularly exciting. Their HIV prep drugs is doing well. However with the Hepatitis C drug coming off patent, they have lost revenues. Deep value but they need to execute. They like the high yield with great premiums on the options. He would rather own another diversified biotech or a basket.
Gilead Sciences Inc.(GILD-Q) Rating
Ranking : 3 out of 5
Bullish - Buy Signals / Votes : 2
Neutral - Hold Signals / Votes : 1
Bearish - Sell Signals / Votes : 3
Total Signals / Votes : 6
Gilead Sciences Inc.(GILD-Q) Frequently Asked Questions
What is Gilead Sciences Inc. stock symbol?
Gilead Sciences Inc. is a American stock, trading under the symbol GILD-Q on the NASDAQ (GILD). It is usually referred to as NASDAQ:GILD or GILD-Q
Is Gilead Sciences Inc. a buy or a sell?
In the last year, 6 stock analysts published opinions about GILD-Q. 2 analysts recommended to BUY the stock. 3 analysts recommended to SELL the stock. The latest stock analyst recommendation is TOP PICK. Read the latest stock experts' ratings for Gilead Sciences Inc..
Is Gilead Sciences Inc. a good investment or a top pick?
Gilead Sciences Inc. was recommended as a Top Pick by The Monthly Gems by Allan Tong on 2020-05-11. Read the latest stock experts ratings for Gilead Sciences Inc..
Why is Gilead Sciences Inc. stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
Is Gilead Sciences Inc. worth watching?
6 stock analysts on Stockchase covered Gilead Sciences Inc. In the last year. It is a trending stock that is worth watching.
What is Gilead Sciences Inc. stock price?
On 2021-07-23, Gilead Sciences Inc. (GILD-Q) stock closed at a price of $69.04.
